Literature DB >> 17544547

Reduced 5-HT2A receptor binding in patients with mild cognitive impairment.

S G Hasselbalch1, K Madsen, C Svarer, L H Pinborg, S Holm, O B Paulson, G Waldemar, G M Knudsen.   

Abstract

Previous studies of patients with Alzheimer's disease (AD) have described reduced brain serotonin 2A (5-HT(2A)) receptor density. It is unclear whether this abnormality sets in early in the course of the disease and whether it is related to early cognitive and neuropsychiatric symptoms. We assessed cerebral 5-HT(2A) receptor binding in patients with mild cognitive impairment (MCI) and related 5-HT(2A) receptor binding to clinical symptoms. Sixteen patients with MCI of the amnestic type (mean age 73, mean MMSE 26.1) and 17 age and sex matched control subjects were studied with MRI and [(18)F]altanserin PET in a bolus-infusion approach. A significant global reduction of 20-30% in 5-HT(2A) binding (atrophy corrected) was found in most neocortical areas. Reduced 5-HT(2A) binding in the striatum correlated significantly with Neuropsychiatric Inventory depression and anxiety scores. We conclude that widespread reductions in 5-HT(2A) receptor binding were found in amnestic MCI, pointing at the presence of serotonergic dysfunction in prodromal AD. This may provide some of the pathophysiological background for the neuropsychiatric symptoms found in early AD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17544547     DOI: 10.1016/j.neurobiolaging.2007.04.011

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  37 in total

Review 1.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

2.  Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT.

Authors:  Andrea Varrone; Nils Sjöholm; Lars Eriksson; Balazs Gulyás; Christer Halldin; Lars Farde
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-13       Impact factor: 9.236

3.  The effect of NAD-299 and TCB-2 on learning and memory, hippocampal BDNF levels and amyloid plaques in Streptozotocin-induced memory deficits in male rats.

Authors:  Simin Afshar; Siamak Shahidi; Ali Haeri Rohani; Alireza Komaki; Sara Soleimani Asl
Journal:  Psychopharmacology (Berl)       Date:  2018-07-19       Impact factor: 4.530

4.  Amygdala functional connectivity is associated with locus of control in the context of cognitive aging.

Authors:  Ping Ren; Mia Anthony; Benjamin P Chapman; Kathi Heffner; Feng Lin
Journal:  Neuropsychologia       Date:  2017-03-14       Impact factor: 3.139

Review 5.  Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection.

Authors:  Shannon L Risacher; Andrew J Saykin
Journal:  Annu Rev Clin Psychol       Date:  2013-01-07       Impact factor: 18.561

Review 6.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

Review 7.  Serotonergic system, cognition, and BPSD in Alzheimer's disease.

Authors:  Saikat Chakraborty; Jack C Lennon; Sridhar A Malkaram; Yan Zeng; Daniel W Fisher; Hongxin Dong
Journal:  Neurosci Lett       Date:  2019-04-01       Impact factor: 3.046

8.  Molecular imaging of serotonin degeneration in mild cognitive impairment.

Authors:  Gwenn S Smith; Frederick S Barrett; Jin Hui Joo; Najlla Nassery; Alena Savonenko; Devin J Sodums; Christopher M Marano; Cynthia A Munro; Jason Brandt; Michael A Kraut; Yun Zhou; Dean F Wong; Clifford I Workman
Journal:  Neurobiol Dis       Date:  2017-05-13       Impact factor: 5.996

9.  Longitudinal assessment of cerebral 5-HT2A receptors in healthy elderly volunteers: an [18F]-altanserin PET study.

Authors:  Lisbeth Marner; Gitte M Knudsen; Steven Haugbøl; Søren Holm; William Baaré; Steen G Hasselbalch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10-01       Impact factor: 9.236

Review 10.  Neuroimaging biomarkers of neurodegenerative diseases and dementia.

Authors:  Shannon L Risacher; Andrew J Saykin
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.